Biosimilars for Management of Crohn Disease

In this issue, Meyer and colleagues report a large and well-conducted cohort study that demonstrates that the effectiveness of the biosimilar CT-P13 is equivalent to that of infliximab in infliximab-naive patients with Crohn disease. The editorialists discuss the results and the assurance they provide about the effectiveness and safety of biosimilars.

https://ift.tt/2GkaoRs